148 related articles for article (PubMed ID: 17374740)
21. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib.
Fahy BN; Schlieman MG; Mortenson MM; Virudachalam S; Bold RJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):46-54. PubMed ID: 15791457
[TBL] [Abstract][Full Text] [Related]
22. The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.
van der Heijden JW; Oerlemans R; Lems WF; Scheper RJ; Dijkmans BA; Jansen G
Clin Exp Rheumatol; 2009; 27(1):92-8. PubMed ID: 19327235
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.
Sun K; Welniak LA; Panoskaltsis-Mortari A; O'Shaughnessy MJ; Liu H; Barao I; Riordan W; Sitcheran R; Wysocki C; Serody JS; Blazar BR; Sayers TJ; Murphy WJ
Proc Natl Acad Sci U S A; 2004 May; 101(21):8120-5. PubMed ID: 15148407
[TBL] [Abstract][Full Text] [Related]
24. [Proteasome inhibitor induces apoptosis and influences the expression of Notch1 and NF-kappaB in multiple myeloma RPMI8226 cells].
Wang H; Liu X; Xu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):531-7. PubMed ID: 18549623
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibition prevents development of experimental dermal fibrosis.
Koca SS; Ozgen M; Dagli F; Tuzcu M; Ozercan IH; Sahin K; Isik A
Inflammation; 2012 Jun; 35(3):810-7. PubMed ID: 21882074
[TBL] [Abstract][Full Text] [Related]
26. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
27. Nuclear factor kappaB inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish embryos.
Daroczi B; Kari G; Ren Q; Dicker AP; Rodeck U
Mol Cancer Ther; 2009 Sep; 8(9):2625-34. PubMed ID: 19723885
[TBL] [Abstract][Full Text] [Related]
28. A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.
Vannucchi AM; Bianchi L; Paoletti F; Pancrazzi A; Torre E; Nishikawa M; Zingariello M; Di Baldassarre A; Rana RA; Lorenzini R; Alfani E; Migliaccio G; Migliaccio AR
Blood; 2005 May; 105(9):3493-501. PubMed ID: 15665119
[TBL] [Abstract][Full Text] [Related]
29. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.
Yanaba K; Yoshizaki A; Muroi E; Hara T; Ogawa F; Shimizu K; Sato S
J Leukoc Biol; 2010 Jul; 88(1):117-22. PubMed ID: 20418448
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
31. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
32. The early marginal zone B cell-initiated T-independent type 2 response resists the proteasome inhibitor bortezomib.
Lang VR; Mielenz D; Neubert K; Böhm C; Schett G; Jäck HM; Voll RE; Meister S
J Immunol; 2010 Nov; 185(9):5637-47. PubMed ID: 20921528
[TBL] [Abstract][Full Text] [Related]
33. Proteasome inhibitor attenuates skeletal muscle reperfusion injury by blocking the pathway of nuclear factor-kappaB activation.
Park JW; Qi WN; Cai Y; Urbaniak JR; Chen LE
Plast Reconstr Surg; 2007 Dec; 120(7):1808-1818. PubMed ID: 18090742
[TBL] [Abstract][Full Text] [Related]
34. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
[TBL] [Abstract][Full Text] [Related]
35. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.
Nencioni A; Schwarzenberg K; Brauer KM; Schmidt SM; Ballestrero A; Grünebach F; Brossart P
Blood; 2006 Jul; 108(2):551-8. PubMed ID: 16537813
[TBL] [Abstract][Full Text] [Related]
36. Elevated thrombopoietin levels in patients with myelofibrosis may not be due to enhanced production of thrombopoietin by bone marrow.
Wang JC; Hashmi G
Leuk Res; 2003 Jan; 27(1):13-7. PubMed ID: 12479847
[TBL] [Abstract][Full Text] [Related]
37. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Cusack JC; Liu R; Houston M; Abendroth K; Elliott PJ; Adams J; Baldwin AS
Cancer Res; 2001 May; 61(9):3535-40. PubMed ID: 11325813
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe M; Sebelin-Wulf K; Beier C; Lietz A; Mathas S; Dörken B; Pezzutto A
Hum Immunol; 2007 Mar; 68(3):147-55. PubMed ID: 17349869
[TBL] [Abstract][Full Text] [Related]
39. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors.
Zheng B; Georgakis GV; Li Y; Bharti A; McConkey D; Aggarwal BB; Younes A
Clin Cancer Res; 2004 May; 10(9):3207-15. PubMed ID: 15131062
[TBL] [Abstract][Full Text] [Related]
40. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
